Literature DB >> 12127561

Establishment and characterization of a new mantle cell lymphoma cell line, Mino.

R Lai1, T J McDonnell, S L O'Connor, L J Medeiros, R Oudat, M Keating, M B Morgan, T J Curiel, R J Ford.   

Abstract

Mantle cell lymphoma (MCL) is a distinct type of B-cell non-Hodgkin's lymphoma characterized by cyclin D1 overexpression and the cytogenetic abnormality, the t(11;14)(q13;q32). MCL cell lines have been difficult to establish and in vitro studies of these neoplasms are scarce. We describe the establishment and characteristics of a new MCL cell line, Mino. The cells are large, growing singly and in small clumps in vitro. By flow cytometry, the immunophenotype was compatible with MCL (i.e. CD5+CD20+CD23-FMC7+). Conventional cytogenetics showed hyperdiploidy with multiple complex karyotypic abnormalities, but no evidence of the t(11;14), proven to be present only by fluorescence in situ hybridization and polymerase chain reaction (PCR) methods. Western blots showed expression of cyclin D1 but no detectable cyclin D2 and cyclin D3; the retinoblastoma protein was predominantly phosphorylated. There was expression of tumor suppressor gene products including p53, p16(INK4a), and p21(WAF1). Sequencing of the TP53 gene revealed a mutation (codon 147(valine-->glycine)) in exon 5. Epstein Barr virus was absent. In summary, Mino is a new MCL cell line that may be useful to study the pathogenesis of MCL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127561     DOI: 10.1016/s0145-2126(02)00013-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  18 in total

1.  PRDM1 is required for mantle cell lymphoma response to bortezomib.

Authors:  Shruti Desai; Michelle Maurin; Matthew A Smith; Sophia C E Bolick; Sophie Dessureault; Jianguo Tao; Eduardo Sotomayor; Kenneth L Wright
Journal:  Mol Cancer Res       Date:  2010-06-08       Impact factor: 5.852

2.  UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells.

Authors:  Samantha A Swenson; Tyler J Gilbreath; Heather Vahle; R Willow Hynes-Smith; Jared H Graham; Henry C-H Law; Catalina Amador; Nicholas T Woods; Michael R Green; Shannon M Buckley
Journal:  Blood       Date:  2020-07-16       Impact factor: 22.113

3.  ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.

Authors:  Rajeswaran Mani; Chi-Ling Chiang; Frank W Frissora; Ribai Yan; Xiaokui Mo; Sivasubramanian Baskar; Christoph Rader; Rebecca Klisovic; Mitch A Phelps; Ching-Shih Chen; Robert J Lee; John C Byrd; Robert Baiocchi; L James Lee; Natarajan Muthusamy
Journal:  Exp Hematol       Date:  2015-04-29       Impact factor: 3.084

4.  CCMCL1: a new model of aggressive mantle cell lymphoma.

Authors:  Xiaoxian Zhao; Selina Chen-Kiang; Shashirekha Shetty; Maurizio Di Liberto; Juraj Bodo; Lisa Durkin; Ken Eng; Olivier Elemento; Mitchell R Smith; Eric D Hsi
Journal:  Blood       Date:  2015-04-23       Impact factor: 22.113

5.  Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease.

Authors:  Lan V Pham; Muychi T Vang; Archito T Tamayo; Gary Lu; Pramoda Challagundla; Jeffrey L Jorgensen; Alex A Rollo; Zhishuo Ou; Liang Zhang; Michael Wang; Richard J Ford
Journal:  Leuk Lymphoma       Date:  2014-04-29

6.  Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Authors:  Lapo Alinari; Bo Yu; Beth A Christian; Fengting Yan; Jungook Shin; Rosa Lapalombella; Erin Hertlein; Mark E Lustberg; Carl Quinion; Xiaoli Zhang; Gerard Lozanski; Natarajan Muthusamy; Mette Prætorius-Ibba; Owen A O'Connor; David M Goldenberg; John C Byrd; Kristie A Blum; Robert A Baiocchi
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

7.  FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.

Authors:  Lapo Alinari; Emilia Mahoney; John Patton; Xiaoli Zhang; Lenguyen Huynh; Christian T Earl; Rajeswaran Mani; Yicheng Mao; Bo Yu; Carl Quinion; William H Towns; Ching-Shih Chen; David M Goldenberg; Kristie A Blum; John C Byrd; Natarajan Muthusamy; Mette Praetorius-Ibba; Robert A Baiocchi
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

8.  Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.

Authors:  A B Gladden; R Woolery; P Aggarwal; M A Wasik; J A Diehl
Journal:  Oncogene       Date:  2006-02-16       Impact factor: 9.867

9.  MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.

Authors:  Yoko Tabe; Denise Sebasigari; Linhua Jin; Martina Rudelius; Theresa Davies-Hill; Kazunori Miyake; Takashi Miida; Stefania Pittaluga; Mark Raffeld
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

10.  Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.

Authors:  Qingshan Yang; Lisa S Chen; Min Jin Ha; Kim-Anh Do; Sattva S Neelapu; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2016-06-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.